OptiBiotix has expanded distribution of its CholBiomex3 to pharmacies in Russia and Kazakhstan. The move has been in collaboration with distribution company SilvExpo. SilvExpo is headquartered in Latvia.
OptiBiotix, a UK-based company, has chosen SilvExpo as its distributor partner to reach Eastern Europe, its target market.
Commenting on the expansion Per Rehné, OptiBiotix Health Commercial Director, said: “This agreement is a strategic step towards constructing a distribution sales channel for CholBiome in Eastern Europe, which we expect to generate revenues quickly.”
It is estimated that 56% of deaths in Russia and Kazakhstan results from cardiovascular disease. The illness is often caused or reinforced by cholesterol.
LPLDL, an ingredient in CholBiomex3, has lowered total cholesterol levels by about 36.7% and offers a natural, scientifically founded alternative with no known side effects.
Probiotix is a subsidiary of Optobiotix that produces CholBiomex3.
CholBiomex3 is produced by Probiotix, a subsidiary of Optobiotix
